Table 2 Laboratory findings, corticosteroid usage, and hospital course in patients with SARS-CoV-2 pneumonia
Non-severe (n = 35) | Severe (n = 23) | P value | |
|---|---|---|---|
Laboratory findings | |||
WBCs count, × 109 /L | 5·1 (1·9) | 5·9 (4·1) | 0·3 |
Lymphocyte count, × 109 /L | 1·3 (0·4) | 0·9 (0·4) | 0·0 |
C-reactive protein, mg/L | 4·5 (0·6–10·9) | 16·8 (3·9–55·8) | 0·0 |
D-dimer, mg/L | 90·0 (45·5–180·0) | 154·0 (113·3–470·5) | 0·1 |
ALT level, IU/L | 20·9 (8·9) | 28·3 (22·4) | 0·1 |
AST level, IU/L | 24·0 (6·3) | 31·0 (13·3) | 0·0 |
Corticosteroid usage | 0·0 | ||
Yes | 11 (31·4%) | 14 (60·9%) | |
No | 24 (68·6%) | 9 (39·1%) | |
Hospital course | |||
Time from onset of illness to antiviral treatment, days | 3·0 (1·0–7·0) | 4·0 (2·0–6·0) | 0·6 |
Clinical recovery time, days | 8·3 (4·7) | 12·9 (4·4) | 0·0 |
Time of virus nucleic acid turn to negative, days | 11·8 (5·0) | 15·7 (6·7) | 0·0 |
Hospitalization duration, days | 14·4 (4·3) | 20·7 (1·2) | 0·0 |